Phase III AXIS trial for second-line metastatic renal cell carcinoma (mRCC): Effect of prior first-line treatment duration and axitinib dose titration on axitinib efficacy.
Brian I. Rini
Consultant or Advisory Role - Pfizer
Research Funding - Pfizer
Bernard J. Escudier
Consultant or Advisory Role - Pfizer
Honoraria - Pfizer
M Dror Michaelson
No relevant relationships to disclose
Sylvie Negrier
Honoraria - Pfizer
Research Funding - Pfizer
Martin Eric Gore
Consultant or Advisory Role - Pfizer
Honoraria - Pfizer
Stephane Oudard
Consultant or Advisory Role - Pfizer
Joseph Clark
No relevant relationships to disclose
Jamal Christo Tarazi
Employment or Leadership Position - Pfizer
Stock Ownership - Pfizer
Brad Rosbrook
Employment or Leadership Position - Pfizer
Stock Ownership - Pfizer
Sinil Kim
Employment or Leadership Position - Pfizer
Stock Ownership - Pfizer
Robert John Motzer
Consultant or Advisory Role - Pfizer
Research Funding - Pfizer